Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(01): 16-20
DOI: 10.4103/sajc.sajc_196_17
ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancer

Assessment of quality of life in resectable gastric cancer patients undergoing chemoradiotherapy as adjuvant treatmentLetter to the Editor

Deep Shankar Pruthi
Department of Radiotherapy, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand
,
Mushtaq Ahmad
Department of Radiotherapy, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand
,
Meenu Gupta
Department of Radiotherapy, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand
,
Saurabh Bansal
Department of Radiotherapy, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand
,
Vipul Nautiyal
Department of Radiotherapy, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand
,
Sunil Saini
Department of Surgical Oncology, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhandd, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Introduction: Quality of life (QOL) is increasingly recognized as an important endpoint in cancer therapies. However, few data are available on QOL in patients who have received radiotherapy as adjuvant treatment for cancer stomach. Methods: Thirty patients who underwent curative resection were enrolled and received chemoradiotherapy (45 Gy in 25 fractions using three-dimensional conformal radiotherapy technique), together with 5-fluorouracil and leucovorin. The European Organization for Research and Treatment of Cancer QOL questionnaire C30 and STO Q22 was assessed at four time points: pre- and postchemoradiotherapy and at 1-month and 6-month follow-up. Results: Mean age of the patients was 54 years. Male:female ratio was 4:1. Stage II and Stage III disease was present in 60% and 30% of patients, respectively. All patients were able to complete the chemoradiotherapy protocol. Our study found out significant impairment in QOL for emotional functioning, fatigue, nausea and vomiting and dyspnea. Results showed that QOL levels decrease postchemoradiotherapy; however, QOL levels returned to baseline at 1-month and 6-month follow-up period. Conclusion: Chemoradiotherapy as adjuvant treatment for cancer stomach patients who have undergone resection with curative intent is a safe and well-tolerated regimen with respect to QOL.

Key words

Chemoradiotherapy - gastric cancer - quality of life


Publication History

Article published online:
22 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin D, et al. GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide: IARC Cancer Base 14 No. 10. Int J Can 2015;136:E359–86.
  • 2 Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 2013;16:1-27.
  • 3 Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, et al. Cancer mortality in India: A nationally representative survey. Lancet 2012;379:1807-16.
  • 4 Meyer HJ, Jähne J, Pichlmayr R. Strategies in the surgical treatment of gastric carcinoma. Ann Oncol 1994;5 Suppl 3:33-6.
  • 5 Costa WL Jr., Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, et al. Adjuvant chemoradiotherapy after D2-lymphadenectomy for gastric cancer: The role of N-ratio in patient selection. Results of a single cancer center. Radiat Oncol 2012;7:169.
  • 6 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
  • 7 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
  • 8 Kassam Z, Mackay H, Buckley CA, Fung S, Pintile M, Kim J, et al. Evaluating the impact on quality of life of chemoradiation in gastric cancer. Curr Oncol 2010;17:77-84.
  • 9 Tyrväinen T, Sand J, Sintonen H, Nordback I. Quality of life in the long-term survivors after total gastrectomy for gastric carcinoma. J Surg Oncol 2008;97:121-4.
  • 10 Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004;40:2260-8.
  • 11 Goody RB, Mckay H, Pitcher B, Oza AM, Brierley J, Hyung J, et al. Prospective evaluation of quality of life during a phase I/II study of adjuvant chemotherapy with high precision IGRT for completely resected gastric cancer. J Clin Oncol 2016;34:164.